Today: 14 June 2026
Browse Category

LSE:HLN.L 6 January 2026 - 27 February 2026

Haleon PLC stock ticks up after earnings whiplash; here’s what matters for HLN shares

Haleon PLC stock ticks up after earnings whiplash; here’s what matters for HLN shares

Haleon shares rose 1% to 398.2 pence in early London trading Friday after sharp swings earlier in the week. The company reported 2025 revenue of £11.03 billion and forecast 3%-5% organic revenue growth for 2026, with a £500 million buyback planned. CEO Brian McNamara said U.S. growth is expected to return this year. Haleon’s next trading update is due April 29.
27 February 2026
··
Haleon share price rises in London as HLN stock turns to February results

Haleon share price rises in London as HLN stock turns to February results

Haleon shares rose 0.6% to 373.8 pence in early London trading Friday ahead of an anticipated update on its operating-model reset. Europe’s STOXX 600 index added 0.1% as investors awaited U.S. policy signals and corporate earnings. Haleon Pakistan this week announced a £3.58 million upgrade to its Panadol Liquid packaging line. Investors are seeking clarity on Haleon’s organic revenue growth and margin outlook.
30 January 2026
·

Stock Market Today

  • Indivior's Chief Scientific Officer Sells Shares Amid Stock Rally: Investor Implications
    June 14, 2026, 12:02 AM EDT. Christian Heidbreder, Chief Scientific Officer at Indivior Pharmaceuticals, sold 18,586 shares valued at $707,383 on June 11, 2026, representing 7.54% of his holdings. Post-sale, he retains 227,923 shares worth about $8.69 million, maintaining a 0.18% stake. The sale occurred during a significant stock price surge, with Indivior shares rising 177% over the past year, reflecting strong market performance amid growth in opioid dependence therapies. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, not signaling insider concerns. Indivior's strategy focuses on buprenorphine-based addiction treatments, with $1.29 billion in trailing twelve-month revenue and $252 million net income, underscoring its established market position and ongoing research-led expansion.

Latest articles

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

14 June 2026
Kraft Heinz closed up 0.70% at $24.39, outpacing the S&P 500, as investors weighed its 6.6% dividend yield against falling organic sales, lower adjusted earnings, and cautious analyst targets; the next earnings update is seen as the key test for whether $600 million in marketing and R&D can revive growth and support the stock’s rebound.
Go toTop